相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative
Thomas K. Karikari et al.
MOLECULAR PSYCHIATRY (2021)
Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia
Shorena Janelidze et al.
NATURE MEDICINE (2020)
Brief Cognitive Tests Used in Primary Care Cannot Accurately Differentiate Mild Cognitive Impairment from Subjective Cognitive Decline
Petrazzuoli Ferdinando et al.
JOURNAL OF ALZHEIMERS DISEASE (2020)
The age-related effect on cognitive performance in cognitively healthy elderly is mainly caused by underlying AD pathology or cerebrovascular lesions: implications for cutoffs regarding cognitive impairment
Emma Borland et al.
ALZHEIMERS RESEARCH & THERAPY (2020)
Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer's disease and PET amyloid-positive patient identification
Nicolas R. Barthelemy et al.
ALZHEIMERS RESEARCH & THERAPY (2020)
Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders
Antoine Leuzy et al.
JAMA NEUROLOGY (2020)
Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling data from four cohorts
Thomas K. Karikari et al.
LANCET NEUROLOGY (2020)
A beta deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer's disease
Niklas Mattsson-Carlgren et al.
SCIENCE ADVANCES (2020)
The implications of different approaches to define AT(N) in Alzheimer disease
Niklas Mattsson-Carlgren et al.
NEUROLOGY (2020)
Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders
Sebastian Palmqvist et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer's disease
Nicolas R. Barthelemy et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2020)
Longitudinal plasma p-tau217 is increased in early stages of Alzheimer's disease
Niklas Mattsson-Carlgren et al.
BRAIN (2020)
Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies
Niklas Mattsson-Carlgren et al.
NATURE COMMUNICATIONS (2020)
Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia
Gil D. Rabinovici et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis
Suzanne E. Schindler et al.
NEUROLOGY (2019)
Determining clinically meaningful decline in preclinical Alzheimer disease
Philip S. Insel et al.
NEUROLOGY (2019)
Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease-Related β-Amyloid Status
Sebastian Palmqvist et al.
JAMA NEUROLOGY (2019)
Staging β-Amyloid Pathology With Amyloid Positron Emission Tomography
Niklas Mattsson et al.
JAMA NEUROLOGY (2019)
Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease
Sebastian Palmqvist et al.
EMBO MOLECULAR MEDICINE (2019)
Accurate risk estimation of β-amyloid positivity to identify prodromal Alzheimer's disease: Cross-validation study of practical algorithms
Sebastian Palmqvist et al.
ALZHEIMERS & DEMENTIA (2019)
Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease
Oliver Preische et al.
NATURE MEDICINE (2019)
Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography
Michelle M. Mielke et al.
ALZHEIMERS & DEMENTIA (2018)
CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts
Oskar Hansson et al.
ALZHEIMERS & DEMENTIA (2018)
NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease
Clifford R. Jack et al.
ALZHEIMERS & DEMENTIA (2018)
Tau Kinetics in Neurons and the Human Central Nervous System
Chihiro Sato et al.
NEURON (2018)
Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders
Rik Ossenkoppele et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
The Montreal Cognitive Assessment: Normative Data from a Large Swedish Population-Based Cohort
Emma Borland et al.
JOURNAL OF ALZHEIMERS DISEASE (2017)
Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity
Sebastian Palmqvist et al.
NATURE COMMUNICATIONS (2017)
Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis
Vitaliy Ovod et al.
ALZHEIMERS & DEMENTIA (2017)
Prognostic Accuracy of Mild Cognitive Impairment Subtypes at Different Cut-Off Levels
Mattias Gothlin et al.
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS (2017)
Defining imaging biomarker cut points for brain aging and Alzheimer's disease
Clifford R. Jack et al.
ALZHEIMERS & DEMENTIA (2017)
CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease
Shorena Janelidze et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2016)
Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study
Magnus Gisslen et al.
EBIOMEDICINE (2016)
Alzheimer's Disease Neuroimaging Initiative 2 Clinical Core: Progress and plans
Paul S. Aisen et al.
ALZHEIMERS & DEMENTIA (2015)
Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia A Meta-analysis
Willemijn J. Jansen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Accuracy of Brain Amyloid Detection in Clinical Practice Using Cerebrospinal Fluid β-Amyloid 42 A Cross-Validation Study Against Amyloid Positron Emission Tomography
Sebastian Palmqvist et al.
JAMA NEUROLOGY (2014)
Amyloid deposition, hypometabolism, and longitudinal cognitive decline
Susan M. Landau et al.
ANNALS OF NEUROLOGY (2012)
Comparison of Brief Cognitive Tests and CSF Biomarkers in Predicting Alzheimer's Disease in Mild Cognitive Impairment: Six-Year Follow-Up Study
Sebastian Palmqvist et al.
PLOS ONE (2012)
Factors affecting Aβ plasma levels and their utility as biomarkers in ADNI
Jon B. Toledo et al.
ACTA NEUROPATHOLOGICA (2011)
The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Guy M. McKhann et al.
ALZHEIMERS & DEMENTIA (2011)
Cognitive Impairment Questionnaire (CIMP-QUEST): reported topographic symptoms in MCI and dementia
R. Astrand et al.
ACTA NEUROLOGICA SCANDINAVICA (2010)
The Mayo Clinic Study of Aging: Design and sampling, participation, baseline measures and sample characteristics
Rosebud O. Roberts et al.
NEUROEPIDEMIOLOGY (2008)
Mild cognitive impairment as a diagnostic entity
RC Petersen
JOURNAL OF INTERNAL MEDICINE (2004)
Multimodel inference - understanding AIC and BIC in model selection
KP Burnham et al.
SOCIOLOGICAL METHODS & RESEARCH (2004)
Diagnosing cognitive impairment and dementia in primary health care - a more active approach is needed
M Lopponen et al.
AGE AND AGEING (2003)
The detection of dementia in the primary care setting
VG Valcour et al.
ARCHIVES OF INTERNAL MEDICINE (2000)
分享论文
